Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - Atea Pharmaceuticals ( NASDAQ:AVIR )

6 days ago

On Friday, Atea Pharmaceuticals Inc. AVIR announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for COVID-19.

Ticker	Sentiment	Impact
AVIR	Neutral	57 %